Myrcludex B

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Myrcludex B
Clinical data
Legal status
  • Investigational
Routes of
administration		 Parenteral
Identifiers
ATC code none

Myrcludex B is an experimental drug for the treatment of hepatitis B and D.[1] The first Phase IIa clinical trials with 40 patients concluded in 2014, finding that the drug was well tolerated and, as far as can be said with the limited data, effective against hepatitis B.[2]

Mechanism of action

The hepatitis B virus uses its surface lipopeptide pre-S1 for docking to mature liver cells via their sodium/bile acid cotransporter (NTCP) and subsequently entering the cells. Myrcludex B is a synthetic N-acetylated pre-S1[3][4] that can also dock to NTCP, blocking the virus's entry mechanism.[1]

The drug is also effective against hepatitis D because the hepatitis D virus is only infective in the presence of a hepatitis B virus infection.[1]

References

<templatestyles src="Reflist/styles.css" />

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


<templatestyles src="Asbox/styles.css"></templatestyles>

Stub icon

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.
  1. ↑ 1.0 1.1 1.2 Lua error in package.lua at line 80: module 'strict' not found.
  2. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  3. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  4. ↑ Lua error in package.lua at line 80: module 'strict' not found.
Retrieved from "https://infogalactic.com/w/index.php?title=Myrcludex_B&oldid=685706571"